An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis

This paper provides an educational review covering the consideration of costs for cost-effectiveness analysis (CEA), summarising relevant methods and research from the published literature. Cost data are typically generated by applying appropriate unit costs to healthcare resource-use data for patients. Trial-based evaluations and decision analytic modelling represent the two main vehicles for CEA. The costs to consider will depend on the perspective taken, with conflicting recommendations ranging from focusing solely on healthcare to the broader ‘societal’ perspective. Alternative sources of resource-use are available, including medical records and forms completed by researchers or patients. Different methods are available for the statistical analysis of cost data, although consideration needs to be given to the appropriate methods, given cost data are typically non-normal with a mass point at zero and a long right-hand tail. The choice of covariates for inclusion in econometric models also needs careful consideration, focusing on those that are influential and that will improve balance and precision. Where data are missing, it is important to consider the type of missingness and then apply appropriate analytical methods, such as imputation. Uncertainty around costs should also be reflected to allow for consideration on the impacts of the CEA results on decision uncertainty. Costs should be discounted to account for differential timing, and are typically inflated to a common cost year. The choice of methods and sources of information used when accounting for cost information within CEA will have an effect on the subsequent cost-effectiveness results and how information is presented to decision makers. It is important that the most appropriate methods are used as overlooking the complicated nature of cost data could lead to inaccurate information being given to decision makers.

[1]  Roland R. Ramsahai,et al.  From sample average treatment effect to population average treatment effect on the treated: combining experimental with observational studies to estimate population treatment effects , 2015 .

[2]  K. Claxton,et al.  Discounting in Economic Evaluations , 2018, PharmacoEconomics.

[3]  F. Hamdy,et al.  Validation of the Hospital Episode Statistics Outpatient Dataset in England , 2016, PharmacoEconomics.

[4]  J. Edmans,et al.  Cost-Effectiveness of a Specialist Geriatric Medical Intervention for Frail Older People Discharged from Acute Medical Units: Economic Evaluation in a Two-Centre Randomised Controlled Trial (AMIGOS) , 2015, PloS one.

[5]  Karl Claxton,et al.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.

[6]  A Briggs,et al.  Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. , 1994, Health economics.

[7]  A. Lloyd Special Edition on Utility Measurement, PharmacoEconomics , 2017, PharmacoEconomics.

[8]  P. van Baal,et al.  Future Costs in Cost-Effectiveness Analyses: Past, Present, Future , 2018, PharmacoEconomics.

[9]  G. Tinghög Legitimate basis for discounting 1 Discounting , Preferences , and Paternalism in Cost-Effectiveness Analysis , 2012 .

[10]  Andrew M. Jones,et al.  A quasi‐Monte‐Carlo comparison of parametric and semiparametric regression methods for heavy‐tailed and non‐normal data: an application to healthcare costs , 2015, Journal of the Royal Statistical Society. Series A,.

[11]  Patrick Hamilton,et al.  The economic burden of cancer in the UK: a study of survivors treated with curative intent , 2016, Psycho-oncology.

[12]  Salah Ghabri,et al.  Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution? , 2018, PharmacoEconomics.

[13]  Corine S. Meppelink,et al.  Validation of the short assessment of health literacy (SAHL-D) and short-form development: Rasch analysis , 2019, BMC Medical Research Methodology.

[14]  K. van der Hoek,et al.  Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis. , 2012, Lung cancer.

[15]  K. Land,et al.  An Empirical Evaluation of the Predictive Mean Matching Method for Imputing Missing Values , 1997 .

[16]  G. Tomlinson,et al.  Techniques for estimating health care costs with censored data: an overview for the health services researcher , 2012, ClinicoEconomics and outcomes research : CEOR.

[17]  D. Owens,et al.  State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[18]  M. Sculpher,et al.  Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.

[19]  J. Gladman,et al.  Economic Evaluation of a General Hospital Unit for Older People with Delirium and Dementia (TEAM Randomised Controlled Trial) , 2011, Trials.

[20]  John Brazier,et al.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment , 2017, PharmacoEconomics.

[21]  J. Brazier,et al.  Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. , 2014, Health technology assessment.

[22]  Andrew Briggs,et al.  Transportability of comparative effectiveness and cost-effectiveness between countries. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  Andrew Briggs,et al.  Missing... presumed at random: cost-analysis of incomplete data. , 2003, Health economics.

[24]  S. Walker,et al.  Appropriate perspectives for health care decisions. , 2010 .

[25]  R. M. Harvey,et al.  Nomenclature and criteria for diagnosis of diseases of the heart and great vessels , 1973 .

[26]  M. Rutten-van Mölken,et al.  The Road Not Taken: Transferability Issues in Multinational Trials , 2013, PharmacoEconomics.

[27]  B. Efron Nonparametric estimates of standard error: The jackknife, the bootstrap and other methods , 1981 .

[28]  Jan Kottner,et al.  The exchangeability of self-reports and administrative health care resource use measurements: assessement of the methodological reporting quality. , 2016, Journal of clinical epidemiology.

[29]  M C Hornbrook,et al.  Modeling risk using generalized linear models. , 1999, Journal of health economics.

[30]  Jonathan Karnon,et al.  Model Parameter Estimation and Uncertainty Analysis , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[31]  Paul J Rathouz,et al.  Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. , 2008, Journal of health economics.

[32]  S. Walker,et al.  Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care , 2018, PloS one.

[33]  Mark Sculpher,et al.  Subgroups and Heterogeneity in Cost-Effectiveness Analysis , 2012, PharmacoEconomics.

[34]  Andrew M. Jones Models for Health Care , 2010 .

[35]  Peter Tyrer,et al.  Comparison of alternative methods of collection of service use data for the economic evaluation of health care interventions. , 2007, Health economics.

[36]  Uwe Siebert,et al.  Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[37]  Andrea Manca,et al.  NICE DSU TECHNICAL SUPPORT DOCUMENT 17: THE USE OF OBSERVATIONAL DATA TO INFORM ESTIMATES OF TREATMENT EFFECTIVENESS IN TECHNOLOGY APPRAISAL: METHODS FOR COMPARATIVE INDIVIDUAL PATIENT DATA , 2015 .

[38]  Dyfrig A Hughes,et al.  Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[39]  James Lomas,et al.  Healthcare Cost Regressions: Going Beyond the Mean to Estimate the Full Distribution. , 2015, Health economics.

[40]  Tracey A. Young,et al.  Estimating mean total costs in the presence of censoring , 2012, PharmacoEconomics.

[41]  S. Walker,et al.  Long-term healthcare use and costs in patients with stable coronary artery disease: a population-based cohort using linked health records (CALIBER) , 2016, European heart journal. Quality of care & clinical outcomes.

[42]  I. White,et al.  Review of inverse probability weighting for dealing with missing data , 2013, Statistical methods in medical research.

[43]  M. Drummond,et al.  Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .

[44]  M Sculpher,et al.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment. , 2004, Health technology assessment.

[45]  Andrew R Willan,et al.  Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. , 2004, Health economics.

[46]  Dyfrig A Hughes,et al.  Methods for the collection of resource use data within clinical trials: a systematic review of studies funded by the UK Health Technology Assessment program. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[47]  Daniel Polsky,et al.  Economic Evaluation in Clinical Trials , 2007 .

[48]  J. Lewsey,et al.  Spoilt for choice: implications of using alternative methods of costing hospital episode statistics. , 2012, Health economics.

[49]  Nigel Rice,et al.  HEALTH ECONOMETRICS , 2018 .

[50]  C. Dirksen,et al.  How to Deal with Cost Differences at Baseline , 2012, PharmacoEconomics.

[51]  Karl Claxton,et al.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.

[52]  M. Davies,et al.  Hospital episode statistics: improving the quality and value of hospital data: a national internet e-survey of hospital consultants , 2012, BMJ Open.

[53]  Miquel Porta,et al.  A Dictionary of Epidemiology , 2008 .

[54]  Mirjam Kretzschmar,et al.  Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5 , 2012, Value in Health.

[55]  A. Vassall,et al.  Cost-Effectiveness Thresholds in Global Health: Taking a Multisectoral Perspective. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[56]  D. Rubin,et al.  Statistical Analysis with Missing Data , 1988 .

[57]  Karl Claxton,et al.  Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[58]  J. Brazier,et al.  A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models , 2017, PharmacoEconomics.

[59]  J. Heckman The Common Structure of Statistical Models of Truncation, Sample Selection and Limited Dependent Variables and a Simple Estimator for Such Models , 1976 .

[60]  A. Akobeng Understanding randomised controlled trials , 2005, Archives of Disease in Childhood.

[61]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[62]  K Claxton,et al.  The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. , 1999, Journal of health economics.

[63]  S. Thompson,et al.  Multiple regression of cost data: use of generalised linear models , 2004, Journal of health services research & policy.

[64]  James R Carpenter,et al.  Missing data in trial‐based cost‐effectiveness analysis: An incomplete journey , 2018, Health economics.

[65]  T. Trikalinos,et al.  Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. , 2016, JAMA.

[66]  M. Franklin,et al.  Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study , 2017, PharmacoEconomics.

[67]  Andrew R Willan,et al.  Regression methods for cost‐effectiveness analysis with censored data , 2005, Statistics in medicine.

[68]  D. Rowen,et al.  International Regulations and Recommendations for Utility Data for Health Technology Assessment , 2017, PharmacoEconomics.

[69]  Karl Claxton,et al.  Discounting and decision making in the economic evaluation of health-care technologies. , 2011, Health economics.

[70]  Spiros C. Denaxas,et al.  Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study , 2013, BMJ.

[71]  Jonathan Karnon,et al.  Modeling Using Discrete Event Simulation , 2012 .

[72]  Richard Grieve,et al.  Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[73]  M Sculpher,et al.  EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. , 2012, Health technology assessment.

[74]  Cost, context and decisions in Health Economics and cost-effectiveness analysis , 2018 .

[75]  T. Roberts,et al.  Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies , 2015, PloS one.

[76]  B. Winblad,et al.  Application of Resource Utilization in Dementia (RUD) instrument in a global setting , 2013, Alzheimer's & Dementia.

[77]  Mark J Sculpher,et al.  Dangerous omissions: the consequences of ignoring decision uncertainty. , 2011, Health economics.

[78]  R. Deyo,et al.  Generic and Disease-Specific Measures in Assessing Health Status and Quality of Life , 1989, Medical care.

[79]  Core items for a standardized resource-use measure (ISRUM) , 2017 .

[80]  Matthew Franklin,et al.  Self-reported and routinely collected electronic healthcare resource-use data for trial-based economic evaluations: the current state of play in England and considerations for the future , 2019, BMC Medical Research Methodology.

[81]  Martin Knapp,et al.  Resource-Use Measurement Based on Patient Recall: Issues and Challenges for Economic Evaluation , 2013, Applied Health Economics and Health Policy.

[82]  Anthony O'Hagan,et al.  Review of Statistical Methods for Analysing Healthcare Resources and Costs , 2010, Health economics.

[83]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[84]  Jonathan Karnon,et al.  Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[85]  Nicholas R Latimer,et al.  Survival Analysis for Economic Evaluations Alongside Clinical Trials—Extrapolation with Patient-Level Data , 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

[86]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[87]  Andrea Manca,et al.  Calculation of quality adjusted life years in the published literature: a review of methodology and transparency. , 2004, Health economics.

[88]  Identifying patient-level health and social care costs for older adults discharged from acute medical units in England. , 2014, Age and ageing.

[89]  M. Yeh,et al.  A real world cost effectiveness analysis of interferon‐based therapy for HCV naïve super‐responders , 2018, Journal of the Chinese Medical Association : JCMA.

[90]  David Moher,et al.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[91]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[92]  Martin Knapp,et al.  Costing psychiatric interventions. , 1992 .

[93]  J. Lewis,et al.  Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. , 1999, Statistics in medicine.

[94]  Sylvie Chevret,et al.  A multiple imputation approach for MNAR mechanisms compatible with Heckman's model , 2016, Statistics in medicine.

[95]  R. Goeree,et al.  The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions , 2012, PharmacoEconomics.

[96]  W. Manning,et al.  Estimating Log Models: To Transform or Not to Transform? , 1999, Journal of health economics.

[97]  N. Freemantle,et al.  An Educational Review of the Statistical Issues in Analysing Utility Data for Cost-Utility Analysis , 2015, PharmacoEconomics.

[98]  M. Drummond,et al.  Whither trial-based economic evaluation for health care decision making? , 2006, Health economics.

[99]  P. Deb,et al.  Modeling Health Care Expenditures and Use. , 2018, Annual review of public health.

[100]  John Van Hoewyk,et al.  A multivariate technique for multiply imputing missing values using a sequence of regression models , 2001 .

[101]  S. Willich,et al.  Economic analysis based on multinational studies: methods for adapting findings to national contexts , 2010, Journal of Public Health.

[102]  A. Basu,et al.  Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. , 2005, Biostatistics.

[103]  A H Briggs,et al.  Handling uncertainty when performing economic evaluation of healthcare interventions. , 1999, Health technology assessment.

[104]  M. Deidda,et al.  A framework for conducting economic evaluations alongside natural experiments , 2019, Social science & medicine.

[105]  P. Deb,et al.  Modeling Health Care Costs and Counts , 2010 .

[106]  K Claxton,et al.  Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development. , 2012, Health technology assessment.

[107]  D. Kendrick,et al.  Identification of incident poisoning, fracture and burn events using linked primary care, secondary care and mortality data from England: implications for research and surveillance , 2015, Injury Prevention.

[108]  A. Monfort,et al.  Fourth Order Pseudo Maximum Likelihood Methods , 2008 .

[109]  L. Seymour,et al.  Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. , 2010, Journal of the National Cancer Institute.

[110]  E. Faerstein,et al.  A DICTIONARY OF EPIDEMIOLOGY , 2016 .

[111]  Peisong Han,et al.  Combining Inverse Probability Weighting and Multiple Imputation to Improve Robustness of Estimation , 2016 .

[112]  Alec Morton,et al.  Health care input constraints and cost effectiveness analysis decision rules , 2018, Social science & medicine.

[113]  S. Walker,et al.  Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities , 2016, PharmacoEconomics.

[114]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.